Cargando…

Lessons learned from human HIV vaccine trials

PURPOSE OF REVIEW: The ability to induce broadly neutralizing antibody (bNAb) responses is likely essential for development of a globally effective HIV vaccine. Unfortunately, human vaccine trials conducted to date have failed to elicit broad plasma neutralization of primary virus isolates. Despite...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pollara, Justin, Easterhoff, David, Fouda, Genevieve G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	HIV AND NOVEL STRATEGIES FOR INDUCTION OF BROAD NEUTRALIZING ANTIBODIES FOLLOWING VACCINATION: Edited by Ralf Wagner
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389590/ https://www.ncbi.nlm.nih.gov/pubmed/28230655 http://dx.doi.org/10.1097/COH.0000000000000362

Ejemplares similares

Stabilized HIV-1 envelope glycoprotein trimers for vaccine use
por: Medina-Ramírez, Max, et al.
Publicado: (2017)

Engineering antibody-like inhibitors to prevent and treat HIV-1 infection
por: Gardner, Matthew R., et al.
Publicado: (2017)

Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses
por: Raman, Sathya N. Thulasi, et al.
Publicado: (2023)

Coronavac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities
por: Wang, Lili, et al.
Publicado: (2023)

Protection against homo and hetero-subtypic inﬂuenza A virus by optimized M2e DNA vaccine
por: Yao, Yanfeng, et al.
Publicado: (2019)

Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages
por: Guo, Li, et al.
Publicado: (2023)

Mass vaccinations against COVID-19 through the use of technologies for the management of appointment scheduling and data of large volumes of vaccinated()
por: Rodas-Martinez, Alicia K., et al.
Publicado: (2022)

Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model
por: Amanat, Fatima, et al.
Publicado: (2019)

Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism
por: Du, Ruixiao, et al.
Publicado: (2022)

Recovering vaccine coverage lost due to the COVID-19 pandemic()
por: Moraga-Llop, F.A., et al.
Publicado: (2020)

Selection of new COVID-19 genotypes following mass vaccination: The Rotavirus model
por: Lapolla, Pierfrancesco, et al.
Publicado: (2022)

Adenoviral vector-based COVID-19 vaccines-associated cerebral venous sinus thromboses: Are those adverse events related to the formation of neutrophil extracellular traps?
por: Simka, Marian
Publicado: (2022)

Advancements in the development of nucleic acid vaccines for syphilis prevention and control
por: Li, Sijia, et al.
Publicado: (2023)

Challenges in development of vaccines directed toward antimicrobial resistant bacterial species
por: Brazzoli, Michela, et al.
Publicado: (2023)

Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial
por: Galgani, Ilaria, et al.
Publicado: (2023)

Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally
por: Liao, Yun, et al.
Publicado: (2023)

Acceptability for the influenza virus vector COVID-19 vaccine for intranasal spray: A cross-sectional survey in Beijing, China
por: Ma, Yuan, et al.
Publicado: (2023)

Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10–50 years old: Randomized, blinded, parallel controlled phase III clinical study
por: Huang, Xiaoyuan, et al.
Publicado: (2023)

Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial
por: López, Pio, et al.
Publicado: (2023)

A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal
por: Chaudhary, Shipra, et al.
Publicado: (2023)

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
por: Patel, Sanjay S., et al.
Publicado: (2023)

Establishment of the 1st Chinese national standard for CA6 neutralizing antibody
por: Wang, Yiping, et al.
Publicado: (2023)

The applications of animal models in phage therapy: An update
por: Mehmood Khan, Fazal, et al.
Publicado: (2023)

Analysis and prediction of the incidence and prevalence trends of gonorrhea in China
por: Chen, Xueya, et al.
Publicado: (2023)

Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV
por: Zolla-Pazner, Susan, et al.
Publicado: (2019)

Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms
por: Brouwer, Philip J.M., et al.
Publicado: (2019)

Immune camouflage: Relevance to vaccines and human immunology
por: De Groot, Anne S, et al.
Publicado: (2014)

Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage
por: Wagh, Kshitij, et al.
Publicado: (2023)

Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses
por: Shoushtari, Mohammad, et al.
Publicado: (2022)

A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable development
por: Berlanda Scorza, Francesco, et al.
Publicado: (2022)

The far-right and anti-vaccine attitudes: lessons from Spain’s mass COVID-19 vaccine roll-out
por: Serrano-Alarcón, Manuel, et al.
Publicado: (2023)

Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches
por: Absalon, Judith, et al.
Publicado: (2022)

Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development
por: Haynes, Barton F., et al.
Publicado: (2023)

Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models
por: Pollara, Justin, et al.
Publicado: (2019)

Lessons from acute HIV infection
por: Robb, Merlin L., et al.
Publicado: (2016)

HIV-1 genetic diversity a challenge for AIDS vaccine development: a retrospective bibliometric analysis
por: Rashid, Abdur, et al.
Publicado: (2022)

‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’
por: Stamatatos, Leonidas
Publicado: (2023)

Revisiting regulatory framework in India for accelerated vaccine development in pandemics with an evidence-based fast-tracking strategy
por: Dinda, Amit Kumar, et al.
Publicado: (2020)

Accelerating HIV vaccine development through meaningful engagement of local scientists and communities
por: Chinyenze, Kundai, et al.
Publicado: (2023)

Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine
por: Martin, Troy M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nrik6tcs2fs5f4d09pnt9omgov